MedPath

A Pharmacokinetic Study of Three Different Particle Sizes of PH-797804

Phase 1
Withdrawn
Conditions
Healthy
Interventions
Registration Number
NCT01924650
Lead Sponsor
Pfizer
Brief Summary

The purpose of this study is to investigate the effects of varying particle size on the pharmacokinetics of PH-797804

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Healthy male subjects and/or healthy female subjects of non-child bearing potential between the ages of 18 and 55 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical laboratory tests.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight > 50 kg (110 lbs).
Exclusion Criteria
  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • A positive urine drug screen.
  • History of regular alcohol consumption exceeding 14 drinks/week for males.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PH-797804 PARTICLE SIZE 9-11UMPH-797804-
PH-797804 PARTICLE SIZE 9-11UM WITH SLSPH-797804-
PH-797804 PARTICLE SIZE <= 20UM WITH SLSPH-797804-
PH-797804 PARTICLE SIZE <= 5UMPH-797804-
PH-797804 PARTICLE SIZE <= 5UM WITH SLSPH-797804-
PH-797804 PARTICLE SIZE <= 20UMPH-797804-
Primary Outcome Measures
NameTimeMethod
Time to Reach Maximum Observed Plasma Concentration (Tmax)0,2,3,4,5,6,8,12,24,48,72 hours post-dose
Area Under the Curve From Time Zero to Time 72 hours (AUC72)0,2,3,4,5,6,8,12,24,48,72 hours post-dose

Area under the plasma concentration time-curve from zero to 72 hours (AUC72)

Maximum Observed Plasma Concentration (Cmax)0,2,3,4,5,6,8,12,24,48,72 hours post-dose
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.